6505--Metoprolol Tartrate IR Tablets Effective 5/8/2026 - 5/7/2027
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79725R0071
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC Pharmaceuticals), has issued an award notice for the procurement of Metoprolol Tartrate Immediate Release (IR) Tablets. This contract, identified by procurement number 36E79725R0071, is effective from May 8, 2026, through May 7, 2027. The primary objective of this procurement is to ensure a reliable supply of Metoprolol Tartrate IR Tablets, a critical pharmaceutical product used in the management of cardiovascular conditions, for VA healthcare facilities nationwide.
The scope of this contract encompasses the manufacturing and delivery of Metoprolol Tartrate IR Tablets in accordance with the standards and requirements set forth by the VA. The awarded supplier is expected to provide pharmaceutical-grade products that meet all applicable regulatory and quality specifications, ensuring patient safety and therapeutic efficacy. The contract falls under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating its focus on drugs and biologicals.
The contracting entity for this procurement is NAC Pharmaceuticals, a federal office within the Department of Veterans Affairs. The primary point of contact for this award is Ray Roldan, who can be reached at [email protected] or by phone at 708-786-4930 for any inquiries related to the contract. The notice remains active as of its posting date, April 2, 2026, and is accessible via the official SAM.gov portal at the provided URL.
This award notice does not specify any set-aside requirements or special considerations, nor does it detail the procurement type beyond its classification as an award. Contractors interested in future opportunities of a similar nature should note the consistent need for high-quality pharmaceutical products within the VA system, adherence to federal manufacturing standards, and the importance of reliable supply chains to support veteran healthcare.
In summary, this procurement represents the VA’s ongoing commitment to securing essential medications for its patient population, with a focus on quality, compliance, and continuity of care. Contractors with capabilities in pharmaceutical manufacturing and distribution may find similar opportunities aligned with their expertise, particularly those able to meet stringent federal requirements and deliver consistent product quality over the contract lifecycle.